March 2007 Vol 7 Isuue 1 FINAL without suicide .indd ABSTRACT Acute epibulbar infections in humans are one of the most frequently diagnosed eye diseases. The majority of these are thought to be caused by the adenovirus. This review focuses on the features of the human adenovirus eye diseases, mode of trans- mission, signs and symptoms, available interventions, and preventive measures. It is concluded that infection control is still widely accepted to be the key to the management of human adenovirus infection in order to prevent the spread, individual suffering and economic damage. Key words: Adenovirus, Keratoconjunctivitis, Eye, Infection control Adenoviral Keratoconjunctivitis *Alexander Bialasiewicz انيَّة دَّ الغُ بالرواشح ة مَ واملُلْتَحِ رْنِيَّةِ الْتِهابُ القَ اليكساندر بياالسويكز ــببها يس التي العني أمراض صفات على تركز املراجعة هذه الغداني. ــح الراش ــببها يس القرنية وامللتحمة التهاب حاالت معظم أن يعتقد امللخص: تعتبر يَة دِ ُعْ امل رَاضِ األَمْ ةُ افَحَ كَ مُ بأن ــتنتج نس أن ميكن الوقاية. وطرق املتاح، التدخل والعالمات، وكذلك واألعراض االنتقال، وطريقة الغداني، ــح الراش االقتصادي. املعاناة والهدر وتقليل الغداني، الراشح انتقال على السيطرة في األساس احلجر واسع بشكل العدوى. على السيطرة وامللتحمة، العني، القرنية التهاب الغدانية، الكلمات: الرواشح مفتاح *Department of Ophthalmology, Sultan Qaboos University, P.O. Box 35, Al Khod 123, Muscat, Sultanate of Oman Email: alexander@squ.edu.om SULTAN QABOOS UNIVERSITY MEDICAL JOURNAL APRIL 2007 VOL 7, NO. 1 SULTAN QABOOS UNIVERSITY© R E V I E W ACUTE EPIBULBAR INFECTIONS IN HUMANS are one of the most frequently diagnosed eye diseases, comprising 2.3-10% of all oph- thalmological diagnoses, with a prevalence of 0.6-3.5 new cases per 1,000 patients in Oman. Although al- most any microbe can elicit an inflammation in the outer eye, about 92% of these are thought on clinical grounds to be caused by adenovirus-associated epi- demic keratoconjunctivitis. In healthy eyes, most of these infections are self-limited and without late se- quelae, but in compromised surface conditions vision- threatening sequelae may result.1, 2, 3 The identification and notification of patients har- bouring conditions and infections with a high morbid- ity (e.g. loss of workdays, high disability adjusted life years) and with nosocomial relevance is very impor- tant for the economy of a country.3, 4, 5 This overview will focus on the clinical ophthal- mology of adenovirus infections, which plays a key role in this scenario. The ophthalmologist can make a focused differential diagnosis taking a detailed history (contacts, course), asking for symptoms and observing signs by biomicroscopy (localization, type and access of the inflammation). A clinical diagnosis can be es- tablished by a morphological examination and com- plemented by laboratory evidence of the infectious agent to identify the suspected organism.6, 7 Close co- operation with infection control specialists may pre- vent potential harm to the healthy population as well as limit costly laboratory work-ups. A L E X A N D E R B I A L A S I E W I C Z 16 E PI D E MI O L O G Y Follicular epidemic keratoconjunctivitis (EKC): Adenoviruses are the most important and most fre- quent cause of follicular epidemic keratoconjunctivitis (classification according to International Classifica- tion of Dieases 10: B 30.0: keratoconjunctivitis by ad- enovirus, B 30.1: conjunctivitis by adenovirus, B 30.2.: pharyngoconjunctival fever by adenovirus [Table 1].3 Adenovirus infections are responsible for 92% of all keratoconjunctivitis cases, and appear mostly in late winter, spring and early summer.8, 9, 3 The viruses impli- cated are adenovirus HAdV1-11, 14-17, 19-22, 26, 29 and 37. The most frequent types in Europe are HAdV 8>3>7>19/37, in Japan HAdV 8>81>4>19/37>3, and in USA 8, 19, and 37.10, 9, 11, 12 Nosocomial infections have been reported to be associated more often with HAdV8, while HAdV 7, 19, 37 are more often asso- ciated with infections from the environment such as lakes and swimming pools.9, 13, 14, 15 Adenovirus types responsible for nosocomial infections are defined by molecular epidemiologic methods such as genome and subgenome typing.14 Virus shift, appearance of new virus types and simultaneous infections by sev- eral virus types can circumvent the type-specific ac- quired immunity in a population and may result in a new symptomatic outbreak.16, 14, 12, 17, 18 Acute hemorrhagic conjunctivitis: Acute hemorrhagic conjunctivitis can be caused by HAdV8 and (rarely) HAdV11 in addition to enterovi- rus 70, 71 and coxsackievirus A24, B2.3, 19 This adeno- viral inflammation is also self-limited, as symptoms disappear after 6 days, faster than the non-hemor- rhagic variant. ARD-associated keratoconjunctitivis: Adenovirus-associated acute respiratory disease (ARD) with conjunctivitis was first reported in mili- tary recruits during World War II. Epidemics of fe- brile disease with conjunctivitis can be due to water- borne transmission of HAdV4 and HAdV7 from inadequately chlorinated swimming pools and small lakes.20 ARD is most often associated with adenovirus types HAdV4 and HAdV7. TR A N SMI S SI O N Direct inoculation by fingers is to be considered a ma- jor mode of transmission when taking into account that the eyelids and tarsal conjunctiva are touched around 14 times per day involuntarily, and addition- ally voluntarily during make-up or application of facial cosmetics. Person-to-person transmission of adeno- virus 8 is established to primarily occur through the hands of personnel and/or other persons in contact with patients. Outbreaks originating in health units can often be traced down to one or a few health care providers.10, 21, 22, 23, 24 In nosocomial infections inadequate hand washing by health-care personnel between patient contacts and inadequate disinfection of equipment is the main risk factor for an outbreak or an epidemic. In larger teach- ing hospitals (>500 beds), the attack rate of patients with EKC has been estimated at 4.7 per 1000 treat- ment cases. Transmission may also occur as smear droplet infection in crowded health institutions or in overpopulated areas with low personal hygiene and behaviour (HAdV 8, 19). Medical and paramedical staff mainly in ophthalmic units and hospitals are the most frequent sources of infections.15, 6 In addition, the improper use of dropper bottles and vials with con- taminated tips, tonometer tips and other inadequately disinfected contact instruments, inappropriate patch- ing or multiple use of contact lenses are other impor- tant risk factors. C O N TA GI O SI T Y Adenoviruses are exceptionally stable to chemical or physical agents and adverse pH conditions, allowing for prolonged survival outside of the body. Thus the high rate of transmission in an ophthalmic unit, e.g. the contagiosity of adenovirus-associated EKC, can be best understood when considering data of HAdV19 being viable up to 8 days on paper, 9 days on tonome- ter tips, 10 days on textiles and metal and up to 35 days on plastics.25, 26 These results emphasize the need for proper selection and application of germicides for use in disinfecting non-critical surfaces and semi-critical medical devices, such as applanation tonometers, in order to prevent outbreaks of epidemic keratoconjunc- tivitis. The necessity for the implementation of infec- tion control measures also seems to result from these data and the lack of effective medical treatment.27, 28 C L I N I C A L PI C T UR E - A D ULTS Symptoms: Patients diseased with the complex of “epidemic keratoconjunctivitis” complain about unilateral (right or left depending on handedness) itching, tearing, burning and foreign body sensation as well as photo- A D E N O V I R A L K E R AT O C O N J U N C T I V I T I S 17 phobia. In case of acute hemorrhagic conjunctivitis (AHC), extensive epibulbar and tarsal hemorrhages and precervical lymph node enlargement may mani- fest as early as 48 hours after the first symptoms in >90% of patients. Signs: Biomicroscopy reveals a serofibrinous, sometimes mucopurulent exudate, accompanied by chemosis, hyperemia and swelling of the plica [Fig.1]. Tarsal and epibulbar follicles (and petechial hemorrhages in case of HAdV3, 4) [Fig.2] appear. Corneal sensitivity is not affected. After a few days, multifocal non-vascularized, centrally located, nummular corneal infiltrates follow in 95% of cases. They consist of dendritic cells, lym- phocytes, histiocytes and fibroblasts [Fig.3].29 Rarely, a superficial punctate keratitis may present, particu- larly with HAdV8. An esthesiometry should be done in all cases of corneal signs, in order to differentiate potentially blinding herpetic disease from adenovirus infections. Tarsal pseudomembranes, which consist of necrotic tissue and fibrin on an intact epithelial sur- face (caveat: no hemorrhage when being removed), can be seen in acute fulminant disease [Fig. 4], and in association with immunodeficiency syndromes [Fig.5]. They tend to form conjunctival scars and mild symblephara. Preauricular, submandibular and cervical lymph node swelling are typically associated with all adeno- virus infections and can be seen and palpated in acute hemorrhagic conjunctivitis [Fig.6] 48 hours after on- set of symptoms. Lid edema, secondary inflammatory ptosis, and an upper respiratory tract infection as well as severe malaise may accompany some cases. ARD is particularly pronounced in HAdV3 and HAdV4 infec- tions of adults and in HAdV7 and HAdV8 infections in children. Sequelae [Figs.7-8]: The clinical symptoms of EKC and AHC are gener- ally self-limiting after 2-3 weeks respectively 4-6 days, However, even after 2 years nummular corneal lesions (and a decrease in vision from 1.0 to 0.5) can be bi- omicroscopically documented for HAdV8 infections in 47% of patients.30 Adenovirus can be isolated from the conjunctiva of a cohort of patients in a decreas- ing time pattern - about 50% of patients after 10 days are still infective, some remain infective for more than 2 years. In case of AHC, HAdV2, HAdV3, HAdV4, HAdV5, HAdV19 can also be isolated even several months after onset. Any cytopathogenic agents infecting the ocular surface, including the adenovirus, result in a post in- fectious dry eye syndrome due to the loss of goblet cells. This event is clinically relevant in about one third of patients. This may sometimes be difficult to differ- entiate from an ongoing infection. The differential di- agnosis can be made utilizing tests such as Schirmer’s, Bengal rose stain, break-up time, tear film interfer- ence, and impression cytology. Rarely, (sub)epithelial conjunctival scars can de- velop particularly in patients that had experienced fulminant and pseudomembraneous disease and lead to persisting corneal irritation and pain sensation [Fig. 9]. Also, as a sequel to the more serious dry eye syn- dromes with persistent infection and ongoing inflam- mation, mild symblephara can result. Risk factors: The adenovirus reservoir responsible for nosocomial ocular infections is the infected human. The mecha- nisms of transmission include contaminated skin, inorganic devices, secretions, aerosols, and droplets. The environmental ARD-associated adenovirus has a reservoir in pools and lakes. Humans infect them- selves while bathing. C L I N I C A L PI C T UR E – N E O N ATE S Neonatal adenovirus infections involving the eye are rare compared to the frequent bacterial inflamma- tions. Conjunctivitis has been reported in neonates surviving systemic disease.31 Symptoms: Simultaneously bilateral “red eyes“ and tearing can be easily differentiated from the mucopurulent exudate in bacterial infections. Signs: Lacrimal gland swelling, lid edema, conjunctival hy- peremia, and conjunctival papillary reaction can be observed. Table 1: Ophthalmologically relevant adenovi- rus types in Europe Follicular conjunctivitis Ad3, 4, 7 Epidemic keratoconjunctivitis EKC Ad8,19, 37 Acute respiratory disease ARD Ad1–3, 4, 6, 7, 14, 21 Pharyngoconjunctival fever Ad3, 7, 14 A L E X A N D E R B I A L A S I E W I C Z 18 Sequelae The clinical symptoms are self-limited after less than 10 days, and compromising corneal disease and vision impairment have not been reported yet. Risk factors It has been documented in Heidelberg recently that the prior examination of neonates by ophthalmolo- gists for screening of retinopathy of prematurity was the only significant risk factor for subsequent adeno- virus conjunctivitis in the newborn.15 L A B O R ATO RY D I A GN O SI S I N O PH TH A L MO L O G Y In the differential diagnosis of microbial conjuncti- vitis, particularly in immunocompromised patients, a laboratory diagnosis supporting and detailing the clinical impression is desirable. Since sometimes mul- tiple types of adenovirus can contribute to an outbreak or epidemic, typing is of considerable epidemiologic relevance. A Dacron- or wood-tipped applicator for conjunctival swab should be inserted deep enough (caveat: use topical anesthetics and NaCl moisteri- zation for applicators) to scrape epithelial cells. The material can be forwarded in commercially available virus transport media, e.g. VT8 for culture, which is still the reference method, however slow (5-33 days) and troublesome. The more practical method is the quantitative real-time polymerase chain reaction (PCR) to prove nucleic acid of HAdV3, 4, 6, 7, 8, 14, 19, 37, which are particularly important in Europe.6, 7 Enzyme immunoassays are a cheaper and faster op- tion with a high sensitivity of 91%; however, they bear a variable specificity depending on contaminations and false positive results. Even cheaper are direct im- munofluorescence tests, which have a very variable sensitivity and specificity and are therefore currently not recommendable for a molecular epidemiologic in- vestigation. For immune dot-blot tests, the sensitivity is 67-84%32 compared to culture, and for the bedside immunochromatographic test it is 95%.33 TR E ATME N T Prerequisites In all self-limiting diseases the evaluation of treatment trials is difficult. Success concerning the disappearance of the infection is often measured by less organisms to be found at the site of infection, less subjective symp- toms, amelioration of inflammatory signs (e.g. con- junctival hyperemia, exudate, corneal involvement) and decrease of morbidity (e.g. office presentations). Medical - Curative Experimental and clinical success has been reported for topical alpha-interferon, 34 cidofovir, 35 PVP-iodine 5%.36 However, none of these agents could withstand the test of cost-effectiveness or freedom of limiting side-effects. As well, the most promising substance in vitro, cidofovir, has been doubted to be effective at all in clinical trials.37 Currently, N-chlorotaurin, which has been proven to be effective against adenovirus and adenovirus in- fection in vivo and in vitro and has been reported tol- erable is entering a phase III clinical trial. However, data regarding the actual shortening of the disease, the duration of symptoms, and the effect on shedding of the virus in humans have not yet been reported and are difficult to obtain in a self-limiting disease Figure 1: Epidemic keratoconjunctivitis: 20 year old patient featuring conjunctival hyperemia, chemosis, plica swelling and accompanying reac- tive tearing splenic rupture Figure 2: Epidemic keratoconjunctivitis: 16 year old patient with petechial hemorrhages on the subtarsal conjunctiva of the ectropionated upper eyelid ( frequent cytopathogenic effect) A D E N O V I R A L K E R AT O C O N J U N C T I V I T I S 19 anyway.38, 39, 40 The use of antiherpetic medications such as arabino- side, 41 iodine-desoxyuridine, 42 or trifluorothymidine43 has not been successful. Medical - Symptomatic Topical corticosteroids may mitigate the subjective symptoms and may delay or prevent the development of corneal infiltrates. After tapering the corticoster- oids off, a recurrence rate of 30% has been reported.30 It has been documented in animal experiments that the adenoviral replication may increase under the in- fluence of corticosteroids.44 Therefore, the application of corticosteroids may only be legitimate in massive fulminant infections with the intention to prevent symblephara, corneal scarring and permanent vision impairment. A consensus for the use or the dosing in- tervals for corticosteroids does not exist. In only one study topical cyclosporin A has been reported beneficial with regard to the removal or dis- appearance of corneal infiltrates.37 Topical antihistaminics and physical supportive measures such as ice-cold bandages have also been advised.18 Topical combinations of tetracyclines and corti- costeroids are frequently prescribed; however, there is no evidence to support a beneficial symptomatic or curative effect. Medical - Prophylactic Vaccines were developed for HAdV4 and HAdV7 in- fections (ARD associated conjunctivitis), but they were conceived only for preventing ARD among military re- cruits and were never relevant for ophthalmologists.20 Surgical Late sequelae such as persisting scars, irregular shap- ing and irregular astigmatism after EKC may result in a compromised image quality or impairment of vision. In these cases a topography- or wavefront-guided pho- totherapeutic keratectomy may restore vision.45 I N FE C TI O N C O N TR O L General Although the beneficial effect of infection control measures has recently been controversially discussed, the mainstream consensus is to pay strict attention to good infection-control practices that may be effective to stop nosocomial outbreaks of adenovirus-associ- ated disease.24, 6, 5 Disinfecting agents proven to be active in vitro against the virus have been listed in the Environmental Protection Agency46 and RKI/Berlin 4 lists of disinfect- ants. However, the in vitro conditions and interaction between test strains and germicides may not simulate in vivo conditions. For example, HAdV2 and HAdV7, is susceptible to alcohols after 10 minutes of contact time, 47 but adenovirus 8 is resistant to the action of 70% isopropyl alcohol.48 Thus, research results con- cerning hygiene issues in adenovirus infections have often been confusing for the practicing clinician. Maintaining adequate levels of chlorination is nec- essary and effective to prevent swimming pool-associ- ated outbreaks of adenovirus conjunctivitis.24, 20 Ophthalmology – Medical staff The main task of medical staff during an outbreak is strictly to adhere to hand disinfection to prevent Figure 3: Epidemic keratoconjunctivitis: 26 year old patient with one paracentral subepithelial irregularly demarcated “dendritic” corneal infil- trate Figure 4: Epidemic keratoconjunctivitis: 28 year old immunocompetent patient with subconjunc- tival hemorrhages and tarsal pseudomembranes (no hemorrhage at removal) A L E X A N D E R B I A L A S I E W I C Z 20 person-to-person spread of infection using the rec- ommended germicides and gloves for the handling of infectious patients or (potentially) contaminated ma- terials. Of the germicides suitable for use as an anti- septic, 70% ethanol achieved a 3 log 10 reduction un- der four of the five test conditions.49 These measures may limit the spread of EKC acutely and may achieve a long-term reduction of incidence rates.50, 32, 9 In a convincing comparative 6-year study employ- ing enforced infection control measures in an oph- thalmic unit, 0.54 outbreaks involving 5.66 infected patients per 10,000 patient examinations have been documented in contrast to 3.89 outbreaks involving 54.09 infected patients per 10,000 patient examinations without those measures (p<0.005 und p<0.0005).13 Physicians suffering from adenovirus conjunctivi- tis should in any case be restricted from working with patients. This results from a study in Canada when an outbreak of EKC could be traced back to 4 of 20 doc- tors of a health centre being responsible for 61% of the infections.51 Hand disinfection after glove removal should be performed using 80% ethanol for at least 5 minutes. or using tosylchloramide sodium 1% or 2% for at least 1 minute.4 Hand washing with a detergent is not suf- ficient. Hand towels must be single use paper and not reusable cotton towels. Ophthalmology – equipment etc: Dropping bottles and eye ointment should only be used by one patient, and single-use units should be preferred.52 Patient-relevant areas, equipment, instruments, and other devices undergoing patient contact like slit lamp accessories must be disinfected with recom- mended germicides.46, 4, 49 Tonometry: Contact tonometry with the Schitz tonometer or the applanation tonometer is a risk factor for EKC, and the pneumotonometer has also has been associated with nosocomial EKC outbreaks.24, 53 Problems regarding disinfection or sterilization of the tonometers particu- larly the disassemblement have been elucidated.54, 55 Tonometers vary in design and material composition; therefore, disinfection or sterilization procedures that are appropriate for one type of tonometer may not be suitable for another.55, 56, 57 Adequate disinfection or sterilization cannot be achieved if the instruments are not initially cleaned thoroughly of any organic mate- rial that can impede contact between the disinfectant and the microorganism during the disinfection proc- ess. In the absence of controlled studies, specifically on disinfection or sterilization of the pneumotonometer and other tonometers, the tips of such tonometers must be cleaned, then disinfected or sterilized after each patient use. The irradiation of tonometer tips with ultraviolet light (maximal antiviral effectiveness: 253.7nm) has been proven effective in studies using HAdV2, but it has not been generally recommended due to the vari- able dosages in various adenovirus types (ID90 20.0 to 50.0 mWs/cm2) and undefined exposure times.58, 54 Figure 5: Epidemic keratoconjunctivitis: 35 year old AIDS patient with severe pain and pseudo- membranes on the lower tarsal conjunctiva Figure 6: Acute hemorrhagic conjunctivitis: 81 year old patient 2 days after intraocular pres- sure profile for glaucoma, featuring bilateral massive (sub)conjunctival hemorrhages, lid edema and nonbacterial mucopurulent exudate A D E N O V I R A L K E R AT O C O N J U N C T I V I T I S 21 Other contact instruments: Thermal disinfection is preferred at 93°C 5 minutes in disinfection and cleansing machines, otherwise a viru- cidal 3% formaldehyde solution may be used for soak- ing (4 hours recommended contact), or a more practi- cal 5% tosylchloramide sodium solution (10 minutes. recommended contact) can be applied, for example for three mirror lenses. Chlorhexidine has been tested on contact instruments (eye lid spatula) for screening of ROP patients and thermal disinfection was found to be superior to chlorhexidine, but chlorhexidine was found to be preferable with regard to 70% isopropyl alcohol. However, chlorhexidine is a weak disinfectant and highly irritating for the eye.59 Areas: Patient contact areas such as slit lamp accessories must be treated with virucidal preparations or by meticulous cleansing with 70% ethanol for at least 5 minutes.46, 5 Textiles: Contaminated textiles must be treated with a thermal (90°C, 10 min.) or chemothermal disinfection.47 Other: Ancillary procedures are necessary to control nosoco- mial EKC outbreaks including, 1) cohorting of EKC- infected health-care personnel only with patients known to have EKC, 2) preventing infected personnel from having direct patient contact for up to 14 days following onset in affected personnel, and 3) using unit-dose eye solutions. Control of large epidemics or those that occur in association with a community out- break require more stringent measures, such as triag- ing patients and assigning those suspected of being infected to waiting and examining rooms that are sep- arate from those for uninfected patients and admitting into the clinic only emergency cases, while postponing examination and treatment of elective patients until after the outbreak. N OTI FI C ATI O N Notification of suspects and/or diagnosed cases of nosocomial adenovirus infections is requested by law in most Western countries. In Germany, the outbreak must be notified anonymously according to the Impfs- chutzgesetz (IfSG) § 6 (3.5). If laboratory evidence has been found, the notification must be by name accord- ing to IfSG § 7.5 In the USA, patients must be reported through state health departments to the Epidemiology Branch, Center for Infectious Diseases, Atlanta.20 R E F E R E N C E S 1. Krumpaszky HG, Klauss V. Epidemiology of blindness and eye diseases. Ophthalmologica 1996; 210:1-84. 2. Bialasiewicz AA. Nosocomial keratitis. Hyg Med, 2000; 11:458-463. 3. Klauss V, Schaller UC, Bialasiewicz AA. Importance and epidemiology of infectious eye diseases. In: Kramer A, Behrens-Baumann W, ed. Antiseptic prophylaxis and therapy in ocular infections. Dev Ophthalmol 2002; 33:145-190. Figure 7: Epidemic keratoconjunctivitis – sequelae: 46 year old patient 7 days after start of clinical symptoms with persistent pronounced central subepithelial corneal infiltrates with a free zone towards the limbus. Photophobia, visual impairment Figure 8: Epidemic keratoconjunctivitis – sequelae: 49 year old patient 5 months after start of clinical symptoms with pronounced cen- tral nonvascularized subepithelial corneal scars and a degenerative iron line. Vision OS cc 0.2, highly irregular astigmatism. A phototherapeu- tic keratectomy was successful, vision increased to 0.8 A L E X A N D E R B I A L A S I E W I C Z 22 4. RKI-Ratgeber Infektionskrankheiten Keratoconjuncti- vitis epidemica und andere Konjunktivitiden durch Ad- enoviren. Merkblätter für Ärzte. Robert Koch Institut, 2004. 5. Bales S, Baumann HG, Schnitzler N. Infektionsschut- zgesetz: Kommentar und Vorschriftensammlung. 2. Auflage. Stuttgart-Berlin: Kohlhammer Verlag, 2003. 6. Cheung D, Bremner J, Chan JT. Epidemic keratocon- junctivitis - do outbreaks have to be epidemic? Eye 2003; 17:356-363. 7. Wolfel R, Pfeffer M, Essbauer S, Nerkelun S, Dobler G. Evaluation of sampling technique and transport media for the diagnostics of adenoviral eye infections/Adeno- virus sampling and transport. Graefes Arch Clin Exp Ophthalmol 2006; 244:1497-1504. Epub 21 March 2006 8. Mueller AJ, Klauss V. Main sources of infection in 145 cases of epidemic keratoconjunctivitis Ger J Ophthal- mol 1993; 2:224-227. 9. Aoki A, Isobe K, Ohno S. Nationwide surveillance pro- gram of epidemic conjunctivitis in Japan. In: Bialasi- ewicz AA, Schaal KP, ed. Infectious diseases of the eye. Philadelphia: Butterworth-Heinemann, 1994. p. 309- 316. 10. D’Angelo LJ, Hierholzer JC, Holman RC, Smith JD. Epi- demic keratoconjunctivitis caused by adenovirus type 8: epidemiologic and laboratory aspects of a large out- break. Am J Epidemiol 1981; 113:44-49. 11. Bialasiewicz AA, Jahn GJ. Augenbefunde bei Virusin- fektionen. Dtsch Arztebl 1994; 91B:685-694. 12. Chang CH, Lin KH, Sheu MM, Huang WL, Wang HZ, Chen CW. The change of etiological agents and clini- cal signs of epidemic viral conjunctivitis over an 18-year period in southern Taiwan. Graefes Arch Clin Exp Oph- thalmol 2003; 241:554-60. 13. Gottsch JD, Froggatt JW 3rd, Smith DM, et al. Preven- tion and control of epidemic keratoconjunctivitis in a teaching eye institute. Ophthalmic Epidemiol 1999; 6:29-39. 14. Takeuchi S, Itoh N, Uchio E, et al. Adenovirus strains of subgenus D associated with nosocomial infection as new etiological agents of epidemic keratoconjunctivitis. J Clin Microbiol 1999; 37:3392-3394. 15. Chaberny IE, Schnitzler P, Geiss HK, Wendt C. An out- break of epidemic keratoconjunctivtis in a pediatric unit due to adenovirus type 8. Infect Control Hosp Epi- demiol 2003; 24:514-519. 16. Kemp MC, Hierholzer JC, Cabradilla CP, Obijeski JF. The changing etiology of epidemic keratoconjunctivitis: antigenic and restriction enzyme analyses of adenovirus types 19 and 37 isolated over a 10 year period. J Infect Dis 1983; 148:24-33. 17. Adhikary AK, Inada T, Banik U, et al. Serological and genetic characterization of a unique strain of adenovi- rus involved in an outbreak of epidemic keratoconjunc- tivitis. J Clin Pathol 2004; 57:411-416. 18. Majeed A, Naeem Z, Khan DA, Ayaz A. Epidemic ade- noviral conjunctivitis report of an outbreak in a military garrison and recommendations for its management and prevention. J Pak Med Assoc 2005; 55:273-275. 19. Bialasiewicz AA. Infektionskrankheiten des Auges. G Fischer Verlag,1995. 20. CDC. Respiratory and Enteric Viruses Branch: Adeno- virus. National Center for Infectious Diseases. www. cdc.gov/ncidod/ Accessed 20 June 2006. 21. Ford E, Nelson KE, Warren D. Epidemiology of epidem- ic keratoconjunctivitis. Epidemiol 1987; 9:244-261 22. Garner JS, Simmons BP. Guideline for isolation precau- tions in hospitals. Atlanta: US Department of Health and Human Services, Public Health Service, CDC. DHHS publication No. 83, 1985. p. 8314. 23. Reilly S, Dhillon BJ, Nkanza KM. Adenovirus type 8 keratoconjunctivitis - an outbreak and its treatment with topical human fibroblast interferon. J Hygiene 1986; 96:557-575. 24. Anonymous. Epidemiologic Notes and Reports: Epi- demic Keratoconjunctivitis in an Ophthalmology Clinic – California. Morbid Mortal Wkly Rep 1990; 39:598- 601. 25. Wegman DH, Guinee VE, Millian SJ. Epidemic kerato- conjunctivitis. Am J Pub Health 1970; 60:1230-1237. 26. Gordon YJ, Gordon RY, Romanowski E, Araullo-Cruz TP. Prolonged recovery of desiccated adenoviral sero- types 5, 8, 19 from plastic and metal surfaces in vitro. Ophthalmology 1993; 100:1835-1839. 27. Wu E, Trauger SA, Pache L, et al. Membrane cofactor protein is a receptor for adenoviruses associated with epidemic keratoconjunctivitis. J Virol 2004; 78:3897- 3905. 28. Bialasiewicz AA, Richard G. Nosokomiale Infektionen am Auge und krankenhaushygienische Massnahmen in der Augenheilkunde. In: Beck EG, Eikmann T, Tilkes F, ed. Hygiene in Krankenhaus und Praxis. Landshut: Ecomed Verlag, 1997. Bd. 8, III/3.19, p. 1-16. 29. Knappe S, Stave J, Guthoff RF. Epidemic keratoconjuncti- vitis. In vivo images of corneal structures with the con- focal Rostocker laser scanning microscope (RLSM)]. Ophthalmologe 2005; 102:798-801. 30. Freyler H, Sehorst W. The fate of corneal infiltrations in cases of epidemic keratoconjunctvitis. Wien Klin Wo- chenschr 1976; 28:341-343. 31. Elnifro EM, Cooper RJ, Dady I, Hany S, Mughal ZM, Klapper PE. Three non-fatal cases of neonatal adenovi- rus infection. J Clin Microbiol 2005; 43:5814-5815. 32. Ankers HE Klapper PE, Cleator GM, Bailey AS, Tulo AB. The role of a rapid diagnostic test (adenovirus im- A D E N O V I R A L K E R AT O C O N J U N C T I V I T I S 23 mune dot-blot) in the control of an outbreak of adenovi- rus type 8 keratoconjunctivitis. Eye 1993; 7:15-17. 33. Fujimoto T, Okafuji T, Okafuji T, et al. Evaluation of a bedside immunochromatographic test for detection of adenovirus in respiratory samples, by comparison to vi- rus isolation and real-time PCR. J Clin Microbiol 2004; 42:5489-5492. 34. Sundmacher R, Wigand R, Cantell K. The value of ex- ogenous interferon in adenovirus keratoconjunctivitis. Graefes Arch Clin Exp Ophthalmol 1982; 218:139-145 35. Gordon YJ, Romanowski EG, Araullo-Cruz T. Topical HPMPC inhibits adenovirus type 5 in the New Zealand rabbit ocular replication model. Invest Ophthalmol Vis Sci 1994; 35:4135-4143. 36. Abel R, Abel AD. Use of PVP iodine in the treatment of presumptive adenoviral conjunctivitis. Ann Ophthal- mol Glaucom 1998; 30:341-343. 37. Hillenkamp J, Reinhard T, Ross RS, et al. Topical treat- ment of adenoviral keratoconjunctivitis with 0.2% ci- dofovir and 1% cyclosporine: a controlled clinical pilot study. Arch Ophthalmol 2001; 119:1487-1491 38. Nagel M, Teuchner B, Pottinger E, Ulmer H, Gottardi W. Tolerance of N-chlorotaurine, a new antimicrobial agent, in infectious conjunctivitis – a phase II pilot study. Ophthalmologica 2000; 214:111-114. 39. Romanowski EG, Yates KA, Teuchner B, Nagl M, Irs- chick EU, Gordon YJ. N-chlorotaurine is an effective antiviral agent against adenovirus in vitro and in the Ad5/NZW rabbit ocular model. Invest Ophthalmol Vis Sci 2006; 47:2021-2026. 40. Teuchner B, Nagl M, Schidlbauer A, et al. Tolerability and efficacy of N-chlorotaurine in epidemic keratocon- junctivitis - a double-blind, randomized, phase-2 clini- cal trial. J Ocul Pharmacol Ther 2005; 21:157-165. 41. Dudgeon J. Treatment of adenovirus infection of the eye with 5-iodo2’-deoxyuridine. Br J Ophthalmol 1969; 53:530-533. 42. Hecht SD, Hanna L, Sery TW, Jawetz E. Treatment of epidemic keratoconjunctivitis with idouxirine. Arch Ophthalmol 1965; 73:49-64 43. Ward JB, Siojo LG, Waller SG. A prospective masked clinical trial of trifluridine, dexamethasone and artificial tears in the treatment of epidemic keratoconjunctivitis. Cornea 1993; 12:216-221. 44. Romanowski EG, Zates KA, Gordon YJ. Topical corti- costeroids of limited potency promote adenovirus rep- lication in the Ad5/NZW rabbit ocular model. Cornea 2002; 21:289-291. 45. Quentin CD, Tondrow M, Vogel M. Photothera- peutische Keratektomie nach Keratokonjunktivitis Epi- demica. Ophthalmologe 1999; 96:92-96. 46. EPA. Antimicrobial Pesticide Products. www.epa.gov, Accessed on 20 June 2006. 47. Klein M, Deforest A. Principles of viral inactivation. In: SM Block, ed. Disinfection, sterilization and preserva- tion. Philadelphia: Lea and Febiger, 1983. p. 422-434. 48. Nagington J, Stehall GM, Whipp P. Tonometer disinfec- tion and viruses. Br J Ophthalmol 1983; 67:674-676. 49. Rutala WA, Peacock JE, Gergen MF, Sobsey MD, Weber DJ. Efficacy of hospital germicides against adenovirus 8, a common cause of epidemic keratoconjunctivitis in health care facilities. Antimicrob Agents Chemother 2006; 50:1419-1424. 50. Buehler JW, Finton RJ, Goodman RA. Epidemic kera- toconjunctivitis: report of an outbreak in an ophthal- mology practice and recommendations for prevention. Infect Control 1984; 5:390-394. 51. Montessori V, Scharf S, Holland S, Werker DH, Roberts FJ, Bryce E. Epidemic keratoconjunctivitis outbreak at a tertiary referral eye care clinic. Am J Infect Control 1998; 26:399-405. 52. Draeger J, Prueter JW. Importance of diagnosis and pr- eoperative care of the conjunctiva. Klin Monatsbl Au- genheilkd 1990; 197:210-213. 53. Warren D, Nelson KE, Farrar JA. A large outbreak of epidemic keratoconjunctivitis: problems in controlling nosocomial spread. J Infect Dis 1989; 160:938-943. 54. Draeger J, Hinzpeter T, Mai K. Tonometer sterilization. Doc Ophthalmol 1969; 26:648-663. 55. Clarke SKR, Hart JCD, Barnard DL. The disinfection of instruments and hands during outbreaks of epidemic keratoconjunctivitis. Trans Ophthalmol Soc U K 1972; 92:613-618. 56. Wood RM. Prevention of infection during tonometry. Arch Ophthalmol 1962; 68:202-218. 57. Corboy JM, Goucher CR, Parnes CA. Mechanical steri- lization of the applanation tonometer. Pt 2. Viral study. Am J Ophthalmol 1971; 71:891-893. 58. Schmitz H, Draeger J, Emmerich P. Tonometer steriliza- tion. The inactivation of HSV 1 and Ad 2 by ultraviolet irradiation. Klin Mbl Augenheilkd 1990; 196:225-227 59. Hutchinson AK, Coats DK, Langdale LM, Steed LL, Demmler G, Saunders RA. Disinfection of eyelid spec- ula with chlorhexidine gluconate (Hibiclens) after ex- aminations for retinopathy of prematurity. Arch Oph-